Positron Emission Tomography for Metastasis

M D Anderson Cancer Center, Houston, TX
Metastasis+2 More ConditionsPositron Emission Tomography - Procedure
Eligibility
18+
All Sexes

Study Summary

This trial is testing how well PET/CT works in assessing patients with head and neck squamous cell cancer that has spread to other places in the body.

Eligible Conditions
  • Head and Neck Squamous Cell Carcinoma
  • Spinal Metastasis
  • Head and Neck Squamous Cell Carcinoma (HNSCC)

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
N/A

Similar Trials

1
Computed Tomography
1
Diagnostic (fluciclovine F18 PET/CT)
1
Diagnostic (89Zr panitumumab PET/CT)

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Up to 6 months

Up to 6 months
Differences in L/B ratio
Optimal imaging time

Trial Safety

Phase-Based Safety

1 of 3

Similar Trials

1
Computed Tomography
1
Diagnostic (fluciclovine F18 PET/CT)
1
Diagnostic (89Zr panitumumab PET/CT)

Side Effects for

CP Responder
69%Platelet count decreased
66%Nausea
47%Neutrophil count decreased
42%Lymphocyte count decreased
36%Diarrhea
28%Vomiting
27%Dyspnea
23%Headache
22%White blood cell decreased
22%Peripheral motor neuropathy
20%Arthralgia
17%Myalgia
17%Paresthesia
16%Fever
11%Dysphagia
8%Laryngopharyngeal dysesthesia
8%Anemia
6%Fatigue
6%Hyperglycemia
5%Thrombotic thrombocytopenic purpura
5%Constipation
5%Flu like symptoms
5%Dehydration
5%Hyponatremia
5%Hypoxia
5%Pain
3%Esophagitis
3%Anorexia
3%Generalized muscle weakness
3%Surgical and medical proced - Oth spec
3%Hypertension
3%Hypotension
3%Blood and lymph sys disorders - Oth Spec
2%Esophageal obstruction
2%Depression
2%Esophageal anastomotic leak
2%Thromboembolic event
2%Cataract
2%Abdominal pain
2%Hearing impaired
2%Endocrine disorders - Other, specify
2%Jejunal fistula
2%Gastroesophageal reflux disease
2%Upper gastrointestinal hemorrhage
2%Cholecystitis
2%Skin infection
2%Urinary tract infection
2%Lymphocyte count increased
2%Hypoalbuminemia
2%Hypokalemia
2%Dizziness
2%Apnea
2%Aspiration
2%Chylothorax
2%Pneumonitis
2%Vascular disorders - Other, specify
2%Atrial fibrillation
2%Ileus
2%Obstruction gastric
This histogram enumerates side effects from a completed 2023 Phase 2 trial (NCT01333033) in the CP Responder ARM group. Side effects include: Platelet count decreased with 69%, Nausea with 66%, Neutrophil count decreased with 47%, Lymphocyte count decreased with 42%, Diarrhea with 36%.

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

Diagnostic (FDG PET/CT)
1 of 1

Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: Positron Emission Tomography · No Placebo Group · N/A

Diagnostic (FDG PET/CT)Experimental Group · 3 Interventions: Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography · Intervention Types: Procedure, Other, Procedure
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Computed Tomography
2017
Completed Phase 2
~2710
Positron Emission Tomography
2008
Completed Phase 2
~2290

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 6 months

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,849 Previous Clinical Trials
1,793,594 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,283 Previous Clinical Trials
41,235,348 Total Patients Enrolled
1 Trials studying Metastasis
2 Patients Enrolled for Metastasis
Jason M JohnsonPrincipal InvestigatorM.D. Anderson Cancer Center
6 Previous Clinical Trials
178 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Frequently Asked Questions

To what extent are individuals being recruited for this trial?

"Affirmative. Clinicaltrials.gov has documented that this clinical trial is accepting participants, with the initial posting date having been June 15th 2018 and a recent update to October 13th 2022 occurring recently. The initiative seeks 50 patients at one site." - Anonymous Online Contributor

Unverified Answer

Are there any available slots in this scientific research project?

"Present data on clinicaltrials.gov suggests that this trial is recruiting participants, having been posted to the site in mid-June 2018 and last updated in late October 2022." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top